Loading…
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $296M | $105M | $24M | $127M | -9.2% | -15.7% | 2629.2% |
| 2024 | $351M | $100M | $1M | $103M | -0.3% | -20.6% | -100.1% |
| 2023 | $443M | $-925M | $-1.0B | $183M | 289.4% | 7.8% | -672.5% |
| 2022 | $411M | $261M | $175M | $274M | 26.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 410.60 | 442.74 | 351.41 | 296.15 |
| Operating Revenue | - | 410.60 | 442.74 | 351.41 | 296.15 |
| Cost Of Revenue | 0 | 0 | - | - | - |
| Gross Profit | 413.75 | 410.60 | - | - | - |
| Operating Expense | - | 160.26 | 274.40 | 255.69 | 177.39 |
| Research And Development | - | 44.26 | 116.08 | 111.42 | 95.14 |
| Selling General And Administration | - | 115.99 | 158.31 | 144.27 | 82.26 |
| Total Expenses | - | 160.26 | 274.40 | 255.69 | 177.39 |
| Operating Income | - | 250.34 | 168.34 | 95.72 | 118.76 |
| Total Operating Income As Reported | - | 250.34 | -945.43 | 93.12 | 98.50 |
| EBITDA | - | 261.44 | -924.86 | 100.24 | 104.65 |
| Normalized EBITDA | - | 261.26 | 188.88 | 102.84 | 124.91 |
| EBIT | - | 260.02 | -926.44 | 98.23 | 102.77 |
| Interest Income | - | 9.50 | 18.97 | 4.47 | 4.08 |
| Interest Expense | - | 7.60 | 21.63 | 33.03 | 32.75 |
| Net Interest Income | - | 1.90 | -2.66 | -28.57 | -28.67 |
| Other Non Operating Income Expenses | - | - | - | 0.64 | 0.19 |
| Other Income Expense | - | 0.18 | -1,113.75 | -1.95 | -20.06 |
| Interest Income Non Operating | - | 9.50 | 18.97 | 4.47 | 4.08 |
| Interest Expense Non Operating | - | 7.60 | 21.63 | 33.03 | 32.75 |
| Net Non Operating Interest Income Expense | - | 1.90 | -2.66 | -28.57 | -28.67 |
| Pretax Income | - | 252.42 | -948.07 | 65.20 | 70.03 |
| Tax Provision | - | 77.36 | 83.49 | 64.32 | 46.01 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0.06 | -233.89 | -0.54 | -4.25 |
| Net Income Continuous Operations | - | 175.06 | -1,031.56 | 0.88 | 24.02 |
| Net Income From Continuing And Discontinued Operation | - | 175.06 | -1,002.24 | 0.88 | 24.02 |
| Net Income From Continuing Operation Net Minority Interest | - | 175.06 | -1,002.24 | 0.88 | 24.02 |
| Net Income | - | 175.06 | -1,002.24 | 0.88 | 24.02 |
| Net Income Common Stockholders | - | 175.06 | -1,002.24 | 0.88 | 24.02 |
| Net Income Including Noncontrolling Interests | - | 175.06 | -1,031.56 | 0.88 | 24.02 |
| Normalized Income | - | 174.94 | -122.38 | 2.93 | 40.02 |
| Diluted NI Availto Com Stockholders | - | 179.51 | -1,002.24 | 0.88 | 24.02 |
| Basic Average Shares | - | 154.37 | 155.44 | 159.08 | 161.84 |
| Diluted Average Shares | - | 186.31 | 155.44 | 160.08 | 162.98 |
| Reconciled Depreciation | - | 1.42 | 1.58 | 2.01 | 1.88 |
| Reconciled Cost Of Revenue | 0 | 0 | - | - | - |
| Total Unusual Items | - | 0.18 | -1,113.75 | -2.59 | -20.26 |
| Total Unusual Items Excluding Goodwill | - | 0.18 | -1,113.75 | -2.59 | -20.26 |
| Minority Interests | 0 | 0 | 29.32 | 0 | - |
| Net Income Discontinuous Operations | 0 | - | - | - | - |
| Special Income Charges | - | 0 | -1,113.77 | -2.59 | -20.26 |
| Other Special Charges | - | - | 1,095.45 | - | - |
| Restructuring And Mergern Acquisition | - | 0 | 18.32 | 2.59 | 20.26 |
| Gain On Sale Of Security | -1.18 | 0.18 | 0.02 | - | - |
| Average Dilution Earnings | 0 | 4.45 | 0 | 0 | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals, Inc.this co. | IRWD | $560M | 23.30 | -2.14 | -9.2% | 9.00 |
| Altimmune, Inc. | ALT | $568M | -6.45 | 2.53 | -39.2% | -6.43 |
| Tactile Systems Technology, Inc. | TCMD | $568M | 29.74 | 2.59 | 8.7% | 12.42 |
| MiMedx Group, Inc. | MDXG | $563M | 11.59 | 2.19 | 18.9% | 5.27 |
| Rigel Pharmaceuticals, Inc. | RIGL |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $560M |
| 1.52 |
| 1.43 |
| 93.8% |
| 4.35 |
| Cytek Biosciences, Inc. | CTKB | $559M | -8.40 | 1.64 | -19.5% | -28.29 |
| Cerus Corporation | CERS | $559M | - | 8.70 | -24.3% | - |
| NeuroPace, Inc. | NPCE | $556M | -25.92 | 29.24 | -112.8% | -50.21 |
| Fulgent Genetics, Inc. | FLGT | $554M | -9.15 | 0.50 | -5.4% | -11.16 |
| Peer Median | - | -6.45 | 2.36 | -12.5% | -6.43 | |